[On-Target] AAV Targeting Bone — Serotypes, Promoters & Dosages: All You Need in One Guide!

The skeleton serves as the structural framework for vertebrates, primarily comprising bone tissue, periosteum, and bone marrow. Bone tissue is classified into rigid, load-bearing compact bone and lightweight, resilient cancellous (spongy) bone. The periosteum envelopes the bone surface, supplying essential nutrients and sensory perception via its rich vascular and neural networks. Within the bone, the bone marrow acts as a critical hematopoietic hub, producing an array of blood cells. Additionally, joints and cartilage play indispensable functional roles. Joints connect separate bones to form a cohesive skeletal system, while cartilage—a smooth, elastic connective tissue—typically covers and protects the ends of long bones as articular cartilage in tetrapods.

Beyond providing structural support and shape, the skeletal system protects vital organs, enables coordinated locomotion, stores essential minerals (such as calcium and phosphorus), and participates in systemic metabolic processes through marrow-derived hematopoiesis. Consequently, maintaining skeletal health is vital for vertebrate survival and physical activity.

Schematic Diagram of Long Bone Structure (From Wikipedia)

Skeletal disorders represent a major frontier in biomedical research, with several conditions receiving intense focus:

• Rheumatoid Arthritis (RA): An autoimmune disorder characterized by joint warmth, swelling, and chronic pain, triggered when the immune system mistakenly attacks intra-articular tissues.
• Osteoporosis: A systemic skeletal disease defined by low bone mass and microarchitectural deterioration of bone tissue, which leads to increased bone fragility and fracture risk.
• Osteoarthritis (OA): A highly prevalent degenerative joint disease where damage to articular cartilage and subchondral bone results in chronic pain, joint stiffness, and physical disability.

Symptoms of Osteoarthritis (PMID:36737426)

Recombinant adeno-associatedvirus (rAAV) vectors have emerged as a cornerstone gene delivery tool in these research domains. Characterized by diverse serotypes, low immunogenicity, and the capacity for long-term stable transgene expression, rAAV is an ideal vehicle for gene therapy. In skeletal research, rAAV vectors can modulate the functions of specific bone cells by delivering therapeutic genes, thereby ameliorating pathological states in diseases like osteoarthritis and offering innovative strategies for treating skeletal disorders.

01 Selection of AAV Serotypes

Different AAV serotypes could be distinguished by variations in their capsid proteins, which dictate distinct tissue tropisms. For skeletal targeting:

• AAV9, AAV-DSS, and AAV8 demonstrate a robust capacity to transduce bone tissues in vivo.
• AAV2 and AAV8 efficiently mediate gene delivery to the articular cartilage and synovium.
• AAV9 and AAV5 are frequently utilized to transduce bone marrow-derived mesenchymal stem cells (BMSCs).
• 
  
• 
  

Intra-articular injection of AAV9 efficiently transduces bone tissue (PMID: 31273195)

Intravenous injection of AAV-DSS targets and transduces the femur （PMID: 31273195）

02 Selection of Promoters

The skeletal system hosts a diverse population of cells. The most heavily investigated include:

• Osteogenic cells: The resident stem cells of bone tissue, which proliferate and differentiate into osteoblasts during bone growth, remodeling, and repair.
• Osteoblasts: Derived from osteogenic cells, they secrete collagen to form the organic bone matrix, eventually becoming embedded as osteocytes as the matrix mineralizes.
• Osteocytes: Differentiated from osteoblasts, they comprise 90%–95% of all bone cells and maintain the bone matrix.
• Osteoclasts: Specialized cells that dissolve bone tissue by releasing various proteases, carbonic anhydrase, and lactic acid.
• Chondrocytes and myeloid cells have also garnered increasing attention in recent studies.
• 
  
• 
  

Bone Cell Types （Wikipedia)

To achieve cell-type-specific transgene expression, selecting an appropriate promoter is critical:

• COL1A1 promoter: Drives expression of the pro-alpha1 chain of type I collagen; widely used to target osteoblasts and fibroblasts.
• COL2A1 promoter: Controls the alpha-1 chain of type II collagen; specifically targets chondrocytes.
• Runx2 promoter: Runx2 is a master transcription factor essential for osteoblast differentiation, maturation, and bone formation, making its promoter ideal for targeting early-stage osteoblasts.
• Osteocalcin (OC) promoter: Osteocalcin is a major non-collagenous matrix protein; its promoter selectively drives expression in osteoblasts, osteocytes, and hypertrophic chondrocytes.
• CD11b promoter: CD11b is a leukocyte surface integrin marker, used to target mature myeloid cells in the bone marrow.

Recommended Promoters for Targeting Skeletal Cells

03 Injection Routes and Dosing Regimens

In AAV-mediated skeletal gene delivery, the most prevalent administration routes are intra-articular (IA), intra-bone marrow (IBM), and intravenous (IV) injections. Specific dosing guidelines are detailed in the table below:

Common Administration Routes and Doses for Skeletal-Targeted AAV

Schematic of intra-bone marrow injection: (a, c) intra-tibial injection; (b, d) intra-iliac injection （PMID: 34112243)

04 Case Study

Case 1: Reversing Osteoporosis via AAV9-Mediated Gene Silencing

Osteoporosis stands as a major global metabolic bone disease. While STARD3NL has been strongly linked to osteoporotic traits, its molecular mechanism in osteoblasts remained elusive. A research team revealed that STARD3NL expression is significantly elevated in bone tissues from patients with low bone mass and mice with ovariectomy (OVX)-induced osteoporosis.

Mechanistically, Stard3nl binds to Anxa2 to suppress β-catenin expression, thereby inhibiting Wnt signaling and downstream osteogenic differentiation. Notably, local knee joint delivery of AAV9-mediated Stard3nl knockdown successfully reversed bone loss in OVX osteoporotic mice. The AAV vectors utilized in this study were engineered by OBIO Technology.

AAV9-mediated Stard3nl silencing prevents bone loss in OVX-induced osteoporosis （PMID: 35098646)

Case 2: Investigating p53 Mutations in Rheumatoid Arthritis

Rheumatoid arthritis is characterized by a disruption in immune homeostasis. Beyond its role as a tumor suppressor, p53 regulates inflammatory and immune responses by modulating the expression of various cytokines and matrix metalloproteinases (MMPs).

Given that p53 mutations have been identified in RA patients, a team investigated the role of p53 in RA pathogenesis. Utilizing OBIO-designed AAV vectors, the researchers established a  adjuvant-induced arthritis (AIA) rat model and evaluated arthritic progression via micro-CT and clinical scoring. The molecular study showed that  interacts with TBK1 to suppress the IRF3-STING cascade, highlighting TBK1 as a viable anti-inflammatory therapeutic target.

Inhibition of arthritis in AIA rats following a single intra-articular injection of AAV-p53R211 (PMID: 37935918)

Case 3: Ameliorating Obesity-Induced Bone Deterioration

Obesity-induced chronic inflammation accelerates tissue degeneration and stem cell dysfunction across multiple organs, yet its precise impact on bone tissues has remained unclear. A study demonstrated that obesity alters the microRNA profile of macrophage-derived extracellular vesicles. This shift impairs the differentiation of skeletal stem/progenitor cells (SSPCs) into osteoblasts while promoting adipogenesis, culminating in bone deterioration.

Screening efforts identified that miR-140 (pro-adipogenic) and miR-378a (pro-osteogenic) synergistically dictate the lineage fate of SSPCs by targeting the Pparα-Abca1 axis. By deploying OBIO-constructed AAV vectors to overexpress miR-378a via intraosseous injection, the researchers successfully mitigated bone mass deterioration in obese mice.

Overexpression of miR-378a rescues obesity-induced osteoporosis (PMID: 39072285)

References

1. Yao Q, Wu X, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):56.

2. Yang YS, Xie J, Wang D, et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat Commun. 2019;10(1):2958.

3. Khattab MS, AbuBakr HO, El Iraqi KG, et al. Intra-iliac bone marrow injection as a novel alternative to intra-tibial inoculation in rat model. Stem Cell Res Ther. 2021;12(1):336.

4. Xu Y, Bao X, Chen X, et al. STARD3NL inhibits the osteogenic differentiation by inactivating the Wnt/β-catenin pathway via binding to Annexin A2 in osteoporosis. J Cell Mol Med. 2022;26(5):1643-1655.

5. Zeng Y, Ng JPL, Wang L, et al. Mutant p53R211* ameliorates inflammatory arthritis in AIA rats via inhibition of TBK1-IRF3 innate immune response. Inflamm Res. 2023;72(12):2199-2219.

6. He C, Hu C, He WZ, et al. Macrophage-derived extracellular vesicles regulate skeletal stem/progenitor Cell lineage fate and bone deterioration in obesity. Bioact Mater. 2024;36:508-523. Published 2024 Jul 4.